News
· 2dFDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they contract respiratory syncytial virus. Previously the vaccine, sold under the name mResvia, was only licensed for use in adults aged 60 and older.
The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...
Visit ESPN for RSV Eintracht live scores, video highlights, and latest news. Find standings and the full 2024-25 season schedule.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback